Author:
He Sun,Shuang Gao,Yinglan Wu,Lan Wang,Wei Wang,Ailing Wang,Changhe Wang,Xiaoyan Wang,Qun Gao,Zechun Lu,Dongxu Huang,Yu Wang,Han Mo Phoenix Kit,Zhongdan Chen,Chan Polin,Qian Wang
Abstract
AbstractPregnant women infected with HCV should be given attention due to their special physiological stage and the effect on offspring health. To examine the prevalence of HCV infection among pregnant women in part of China and explore relevant factors during pregnancy, a cross-sectional study was conducted in four maternal and children health care institutions (MCHC) in Guangdong, Hunan and Chongqing. Pregnant women who were delivered, induced or spontaneous abortion were included and relevant information was collected through the Hospital Information System. Results showed that the prevalence of HCV among pregnant women in four MCHCs was 0.11% (95% CI 0.09–0.13%). Age, occupations, regions, syphilis-infection, intrahepatic cholestasis of pregnancy (ICP), and placenta previa were significant factors (all P < 0.05). Age and syphilis-infection were positively correlated with HCV infection (Z = 3.41, P = 0.0006; OR = 18.16, 95% CI 9.34–35.29). HCV and HBV infection were risk factors of ICP (OR = 4.18, 95% CI 2.18–8.04; OR = 2.59, 95% CI 2.31–2.89). Our study indicates that the prevalence of HCV among pregnant women in the three provinces(city) was low compared with the general population in China. Older age and syphilis-infection increased the risk of HCV infection during pregnancy. HCV infection was a risk factor of ICP. Generally, we need keep a watchful eye on HCV infection and relevant factors mentioned above during pregnancy in clinic, especially those also infected with syphilis. HCV testing based on risk factors is recommended in antenatal care and obstetrics.
Funder
world health organization
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. World Health, O. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016–2021: Actions for Impact. xii, 92 p. (World Health Organization, 2021).
2. Spera, A. M., Eldin, T. K., Tosone, G. & Orlando, R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?. World J. Hepatol. 8, 557–565. https://doi.org/10.4254/wjh.v8.i12.557 (2016).
3. Wang, W. Research progress on the latest transmission route and prevention of hepatitis C. Cap. Med. 28, 11–13. https://doi.org/10.3969/j.issn.1005-8257.2021.08.005 (2021).
4. Benova, L., Mohamoud, Y. A., Calvert, C. & Abu-Raddad, L. J. Vertical transmission of hepatitis C virus: Systematic review and meta-analysis. Clin. Infect. Dis. 59, 765–773. https://doi.org/10.1093/cid/ciu447 (2014).
5. Wen, Z. X., Zhu, P. & Wang, Y. M. Recent progress in clinical research of hepatitis C virus infection in pediatric patients. J. Clin. Hepatol. 2012, 888–892 (2012).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献